Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage.

Brooks, Nathan; Nagaraju, Supriya; Matulay, Justin; Han, Xiang-Yang; Kamat, Ashish M

Brooks, Nathan; Nagaraju, Supriya; Matulay, Justin; Han, Xiang-Yang; Kamat, Ashish M.

Afiliación

Brooks N; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nagaraju S; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Matulay J; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Han XY; Department of pathology and laboratory medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Kamat AM; Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Eur Urol Oncol ; 4(5): 826-828, 2021 10.

Article en En | MEDLINE | ID: mdl-32475716

Asunto(s)

Antineoplásicos; Neoplasias de la Vejiga Urinaria; Antineoplásicos/uso terapéutico; Vacuna BCG/uso terapéutico; Humanos; Inmunoterapia; Recurrencia Local de Neoplasia; Neoplasias de la Vejiga Urinaria/tratamiento farmacológico

Palabras clave

BCG shortage; Bacillus Calmette-Guérin; Bladder cancer; Microbial viability

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Antineoplásicos Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Eur Urol Oncol Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Países Bajos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google